Navigation Links
Pharmacyclics Forms Pact to Develop and Commercialize PCI-32765 for Hematologic Cancers with Janssen Biotech, Inc.
Date:12/8/2011

SUNNYVALE, Calif., Dec. 8, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), announced today that it has entered into a worldwide collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ), to develop and commercialize PCI-32765, a novel, oral, first-in-class Bruton's tyrosine kinase (Btk) inhibitor  being developed for the treatment of Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma, all of which are considered hematological malignancies.  PCI-32765 was developed by Pharmacyclics and is currently in Phase II clinical trials.  

Under the terms of the agreement, Pharmacyclics will receive an upfront payment of $150 million.   In addition, Pharmacyclics will receive up to an additional $825 million in development and regulatory milestone payments, based upon continued development, regulatory progress and approval of the product, for total potential upfront and milestone payments of $975 million. 

Pharmacyclics and Janssen will collaborate on the development of PCI-32765 for oncology and other indications, excluding inflammation and immune mediated conditions.  Each company will lead development for specific indications as stipulated in a global development plan, with development costs shared on a 40/60 basis (Pharmacyclics 40% and Janssen 60%).  The agreement includes plans to launch multiple Phase III trials of PCI-32765 over the next several years.

Following regulatory approval, both Pharmacyclics and Janssen will book revenue and co-commercialize PCI-32765.   In the US, Pharmacyclics will book sales and take a lead role in US commercial strategy development and both Pharmacyclics and Janssen will share in commercialization activities.    Outside the United States, Janssen will book sales a
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), ... that its CGuard TM Embolic Prevention System reported positive ... Musialek , at the EuroPCR conference on May ... PARADIGM, an investigator-initiated P rospective evaluation of ... revascularization I n symptomatic and increased-risk asymptomatic carotid artery ...
(Date:5/22/2015)... 2015 AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ... and commercialization of innovative therapies for the treatment of ... executive officer Howie Rosen will be presenting ... Tim Morris will be presenting at JMP ... are as follows: Jefferies 2015 Healthcare Conference ...
(Date:5/21/2015)... , May 21, 2015 ... announced the addition of the "Market Assessment ... Europe" report to their offering. ,     (Logo: ... of the respiratory imaging diagnostics market in ... Europe . The service provides detailed ...
Breaking Medicine Technology:InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2United States and Europe Respiratory Diagnostics Market Assessment 2015 2
(Date:5/22/2015)... Omar Ahmad Barrada, a junior at ... the 2015 Congress of Future Medical Leaders in Boston, ... of “America’s highest achieving high school students.” , “I’m ... new goals and learn better study habits,” said Omar. ... which we can ask the surgeons questions.” , The ...
(Date:5/22/2015)... NY (PRWEB) May 22, 2015 Hands ... that June 17, 2015, the Annual One Day Sale ... Since 2007, Hands On HCMT offers drastically reduced certificates one ... and estheticians have enough sessions, through what used to be ... is wonderful for the community as well. This once a ...
(Date:5/22/2015)... 22, 2015 Family, friends, students, colleagues, ... surgical oncologist, Dr. LaSalle D. Leffall, on Monday, May ... began after Grand Rounds in the hospital’s Tower Auditorium. ... outside the auditorium, trying to keep the secret. “I’d ... he sees me, he’ll know something is up,” she ...
(Date:5/22/2015)... May 22, 2015 Coordinating care ... difficult process. Historically providers have not been reimbursed ... Starting in 2015, Medicare has paved the way ... Thanks to the launch of Oculus Health ... health systems using the platform will now be ...
(Date:5/22/2015)... According to a new Aegis Living Study on ... likely to worry about what will happen to their memory ... 69% Silent Generation), which may help explain why nearly half ... particularly Millennials (47%), Gen X’ers (51%), and Boomers (43%). The ... among more than 2,000 U.S. adults ages 18+. , ...
Breaking Medicine News(10 mins):Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 3Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4Health News:New Study Reveals America’s Fear of Aging 2Health News:New Study Reveals America’s Fear of Aging 3
... for heart disease, 56% risk of ischemic stroke, study finds ... secondhand smoke at home or in the workplace had a ... to women who weren,t exposed, a new study says. , ... of secondhand smoke on peripheral artery disease in women," lead ...
... are uncovering more evidence that a virus they recently discovered ... deadly form of skin cancer. , The findings, published in ... the National Academy of Sciences, put to rest the ... that were the case, the virus would be a passenger ...
... help women to,take control of their health and improve ... Women today placed the first,bilingual, touch-activated Women,s Wellness Guide ... This is the first of 13 kiosks to ... tendency to care for everyone else but themselves and,their ...
... Sept. 22 Biomoda, Inc.,(OTC Bulletin Board: BMOD) ... expanded its intellectual property portfolio,with approval from the ... and CyPath(R)., "We are pleased to receive ... portfolio," said John Cousins, Biomoda president. "It is ...
... Ill. September 22, 2008 A study appearing ... Journal of Medicine shows that among individuals with no ... risk of colorectal cancer is extremely low. The data provides ... longer after a normal colonoscopic examination. , "This research is ...
... patients who receive stereotactic radiosurgery (SRS) and whole brain ... tumors have more than twice the risk of developing ... alone, according to new research from The University of ... of the phase III randomized trial were presented at ...
Cached Medicine News:Health News:Women's Peripheral Artery Disease Tied to Secondhand Smoke 2Health News:Pitt research indicates new virus is culprit, not bystander, in deadly skin cancer 2Health News:Pennsylvania Commission for Women Delivers First Women's Wellness Guide Kiosk to Allegheny County Jail 2Health News:U.S. Patent Office Grants Biomoda Registration for Trademarks 2Health News:Risk of colorectal cancer extremely low 5 years after a normal colonoscopy screening 2Health News:Whole brain radiation increases risk of learning and memory problems in cancer patients 2Health News:Whole brain radiation increases risk of learning and memory problems in cancer patients 3
Greenberg micro instrument holder is a flexbar arm used to hold micro instruments used repeatedly within retracted fields. Holds instruments with shafts up to 1/8 in diameter....
Greenberg universal retractor case, with four compartments to hold various components....
Length-9 (229 mm) Tapered retractor blades....
Kit is supplied with four secondary bars. Secondary bars attach to primary bar. Length 12 (305 mm)....
Medicine Products: